185 related articles for article (PubMed ID: 21665942)
1. The soluble guanylyl cyclase activator YC-1 increases intracellular cGMP and cAMP via independent mechanisms in INS-1E cells.
Ramos-Espiritu LS; Hess KC; Buck J; Levin LR
J Pharmacol Exp Ther; 2011 Sep; 338(3):925-31. PubMed ID: 21665942
[TBL] [Abstract][Full Text] [Related]
2. Soluble guanylyl cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway.
Hwang TL; Hung HW; Kao SH; Teng CM; Wu CC; Cheng SJ
Mol Pharmacol; 2003 Dec; 64(6):1419-27. PubMed ID: 14645672
[TBL] [Abstract][Full Text] [Related]
3. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity.
Galle J; Zabel U; Hübner U; Hatzelmann A; Wagner B; Wanner C; Schmidt HH
Br J Pharmacol; 1999 May; 127(1):195-203. PubMed ID: 10369473
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of the nitric oxide receptor, soluble guanylyl cyclase, in cerebellar cells.
Bellamy TC; Garthwaite J
Br J Pharmacol; 2002 May; 136(1):95-103. PubMed ID: 11976273
[TBL] [Abstract][Full Text] [Related]
5. Activation of soluble guanylyl cyclase inhibits estradiol production and cyclic AMP accumulation from cultured rat granulosa cells.
Tafoya MA; Chen JY; Stewart RL; Lapolt PS
Fertil Steril; 2004 Oct; 82 Suppl 3():1154-9. PubMed ID: 15474089
[TBL] [Abstract][Full Text] [Related]
6. Human trabecular meshwork cell volume decrease by NO-independent soluble guanylate cyclase activators YC-1 and BAY-58-2667 involves the BKCa ion channel.
Dismuke WM; Sharif NA; Ellis DZ
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3353-9. PubMed ID: 19234350
[TBL] [Abstract][Full Text] [Related]
7. YC-1 potentiates cAMP-induced CREB activation and nitric oxide production in alveolar macrophages.
Hwang TL; Tang MC; Kuo LM; Chang WD; Chung PJ; Chang YW; Fang YC
Toxicol Appl Pharmacol; 2012 Apr; 260(2):193-200. PubMed ID: 22381622
[TBL] [Abstract][Full Text] [Related]
8. YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components.
Martin E; Lee YC; Murad F
Proc Natl Acad Sci U S A; 2001 Nov; 98(23):12938-42. PubMed ID: 11687640
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of tumor necrosis factor-alpha expression by YC-1 in alveolar macrophages through a cyclic GMP-independent pathway.
Hwang TL; Wu CC; Guh JH; Teng CM
Biochem Pharmacol; 2003 Jul; 66(1):149-56. PubMed ID: 12818375
[TBL] [Abstract][Full Text] [Related]
10. Activity of guanylyl cyclase activators on the reaction of tracheal smooth muscle contraction.
Glaza I; Szadujkis-Szadurski L; Szadujkis-Szadurski R; Gajdus M; Rzepka A; Gurtowska N
Postepy Hig Med Dosw (Online); 2011 Aug; 65():496-500. PubMed ID: 21918251
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms involved in the synergistic activation of soluble guanylyl cyclase by YC-1 and nitric oxide in endothelial cells.
Schmidt K; Schrammel A; Koesling D; Mayer B
Mol Pharmacol; 2001 Feb; 59(2):220-4. PubMed ID: 11160856
[TBL] [Abstract][Full Text] [Related]
12. YC-1-inhibited proliferation of rat mesangial cells through suppression of cyclin D1-independent of cGMP pathway and partially reversed by p38 MAPK inhibitor.
Chiang WC; Teng CM; Lin SL; Chen YM; Tsai TJ; Hsieh BS
Eur J Pharmacol; 2005 Jul; 517(1-2):1-10. PubMed ID: 15950964
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1-benzyl-indazole.
Chien WL; Liang KC; Teng CM; Kuo SC; Lee FY; Fu WM
Mol Pharmacol; 2003 Jun; 63(6):1322-8. PubMed ID: 12761342
[TBL] [Abstract][Full Text] [Related]
14. Interference of neutrophil-platelet interaction by YC-1: a cGMP-dependent manner on heterotypic cell-cell interaction.
Liao CH; Cheng JT; Teng CM
Eur J Pharmacol; 2005 Sep; 519(1-2):158-67. PubMed ID: 16112105
[TBL] [Abstract][Full Text] [Related]
15. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators.
Mülsch A; Bauersachs J; Schäfer A; Stasch JP; Kast R; Busse R
Br J Pharmacol; 1997 Feb; 120(4):681-9. PubMed ID: 9051308
[TBL] [Abstract][Full Text] [Related]
16. Soluble guanylyl cyclase activator YC-1 protects white matter axons from nitric oxide toxicity and metabolic stress, probably through Na(+) channel inhibition.
Garthwaite G; Goodwin DA; Neale S; Riddall D; Garthwaite J
Mol Pharmacol; 2002 Jan; 61(1):97-104. PubMed ID: 11752210
[TBL] [Abstract][Full Text] [Related]
17. High and low gain switches for regulation of cAMP efflux concentration: distinct roles for particulate GC- and soluble GC-cGMP-PDE3 signaling in rabbit atria.
Wen JF; Cui X; Jin JY; Kim SM; Kim SZ; Kim SH; Lee HS; Cho KW
Circ Res; 2004 Apr; 94(7):936-43. PubMed ID: 14988225
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of superoxide anion generation by YC-1 in rat neutrophils through cyclic GMP-dependent and -independent mechanisms.
Wang JP; Chang LC; Raung SL; Hsu MF; Huang LJ; Kuo SC
Biochem Pharmacol; 2002 Feb; 63(4):577-85. PubMed ID: 11992625
[TBL] [Abstract][Full Text] [Related]
19. The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.
Reinke Y; Gross S; Eckerle LG; Hertrich I; Busch M; Busch R; Riad A; Rauch BH; Stasch JP; Dörr M; Felix SB
Eur J Pharmacol; 2015 Nov; 767():1-9. PubMed ID: 26407652
[TBL] [Abstract][Full Text] [Related]
20. Activation of soluble guanylyl cyclase by YC-1 in aortic smooth muscle but not in ventricular myocardium from rat.
Wegener JW; Gath I; Förstermann U; Nawrath H
Br J Pharmacol; 1997 Dec; 122(7):1523-9. PubMed ID: 9421305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
